雜志介紹

Clinical Epigenetics雜志介紹

《Clinical Epigenetics》是一本以English為主的開放獲取國際優(yōu)秀期刊，中文名稱臨床表觀遺傳學，本刊主要出版、報道醫(yī)學-GENETICS & HEREDITY領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進展，探討行業(yè)發(fā)展的思路和方法，以促進學術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認可。該刊最新影響因子為4.8，最新CiteScore 指數(shù)為8.9。

本刊近期中國學者發(fā)表的論文主要有：

• Peritoneal cell-free DNA as a sensitive biomarker for detection of peritoneal metastasis in colorectal cancer: a prospective diagnostic study: A prospective diagnostic study

  Author: Yuan, Zixu; Chen, Wenle; Liu, Duo; Qin, Qiyuan; Grady, William M.; Fichera, Alessandro; Wang, Huaiming; Hou, Ting; Lv, Xinze; Li, Chanhe; Wang, Hui; Cai, Jian

• Hepatocellular carcinoma detection via targeted enzymatic methyl sequencing of plasma cell-free DNA

  Author: Guo, Ping; Zheng, Hailing; Li, Yihan; Li, Yuntong; Xiao, Yue; Zheng, Jin; Zhu, Xingqiang; Xu, Huan; He, Zhi; Zhang, Qian; Chen, Jinchun; Qiu, Mingshan; Jiang, Min; Liu, Pingguo; Chen, Hongliang

• Genetic, DNA methylation, and immune profile discrepancies between early-stage single primary lung cancer and synchronous multiple primary lung cancer

  Author: Yu, Fenglei; Huang, Xiaojie; Zhou, Danting; Zhao, Zhenyu; Wu, Fang; Qian, Banglun; Wang, Qiang; Chen, Juan; Liang, Qingchun; Jiang, Yi; Ding, Qi; He, Qiongzhi; Tang, Jingqun; Wang, Xiang; Liu, Wenliang; Chen, Chen

• Inactivation of ZSCAN18 by promoter hypermethylation drives the proliferation via attenuating TP53INP2-mediated autophagy in gastric cancer cells

  Author: Li, Bin; Ren, Baoqing; Ma, Gang; Cai, Fenglin; Wang, Pengliang; Zeng, Yi; Liu, Yong; Zhang, Li; Yang, Yang; Liang, Han; Zhang, Rupeng; Deng, Jingyu

英文介紹

Clinical Epigenetics雜志英文介紹

Clinical Epigenetics, the official journal of the Clinical Epigenetics Society, is an open access, peer-reviewed journal that encompasses all aspects of epigenetic principles and mechanisms in relation to human disease, diagnosis and therapy. Clinical trials and research in disease model organisms are particularly welcome.